Showing 2,141 - 2,160 results of 19,405 for search '(( 59 ((0 decrease) OR (a decrease)) ) OR ( 50 ((we decrease) OR (nn decrease)) ))', query time: 0.85s Refine Results
  1. 2141
  2. 2142
  3. 2143
  4. 2144
  5. 2145
  6. 2146

    Stabilization of Coordinated Carbonate in Aqueous Acidic Solution:  Steric Inhibition of Protonation in Co(III) Complexes Containing Chelated Carbonate<sup>†</sup> by Sarah E. Cheyne (2647126)

    Published 2006
    “…The complexes display very different spectroscopic and <sup>59</sup>Co NMR properties, consistent with the decreasing ligand field strength of the tripodal amine ligands in the order tpa > Me-tpa > Me<sub>2</sub>-tpa > Me<sub>3</sub>-tpa. …”
  7. 2147

    Identification, Synthesis, and Biological Evaluations of Potent Inhibitors Targeting Type I Protein Arginine Methyltransferases by Xiao Li (107004)

    Published 2022
    “…CARM1 (coactivator-associated arginine methyltransferase 1), which belongs to type I PRMTs (protein arginine methyltransferases), is a potential therapeutic target for treatment of multiple cancers. In this study, we first identified several hit compounds against CARM1 by structure-based virtual screening (IC<sub>50</sub> = 35.51 ± 6.68 to 68.70 ± 8.12 μM) and then carried out chemical structural optimizations, leading to six compounds with significantly improved activities targeting CARM1 (IC<sub>50</sub> = 18 ± 2 to 107 ± 6 nM). …”
  8. 2148

    Selective TASK‑1 Inhibitor with a Defined Structure–Activity Relationship Reduces Cancer Cell Proliferation and Viability by Bárbara Arévalo (4053358)

    Published 2022
    “…Chemical structures of selective blockers of TASK channels contain aromatic groups and amide bonds. Using this rationale, we designed and synthesized a series of compounds based on 3-benzamidobenzoic acid. …”
  9. 2149

    Selective TASK‑1 Inhibitor with a Defined Structure–Activity Relationship Reduces Cancer Cell Proliferation and Viability by Bárbara Arévalo (4053358)

    Published 2022
    “…Chemical structures of selective blockers of TASK channels contain aromatic groups and amide bonds. Using this rationale, we designed and synthesized a series of compounds based on 3-benzamidobenzoic acid. …”
  10. 2150

    IDD388 Polyhalogenated Derivatives as Probes for an Improved Structure-Based Selectivity of AKR1B10 Inhibitors by Alexandra Cousido-Siah (777034)

    Published 2016
    “…Next, by means of IC<sub>50</sub> measurements, X-ray crystallography, WaterMap analysis, and advanced binding free energy calculations with a quantum-mechanical (QM) approach, we have studied their structure–activity relationship (SAR) against both enzymes. …”
  11. 2151

    DataSheet_1_Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.docx by Ayantika Sen (13921581)

    Published 2022
    “…The objective of this study was to determine if changes in miR expression are associated with EBV+ PTLD. In this study, we have shown that miR-194 is significantly decreased in EBV+PTLD tumors and that additional miRs, including miRs-17, 19 and 106a are also reduced in EBV+PTLD as compared to EBV-PTLD. …”
  12. 2152

    DataSheet_1_Host microRNAs are decreased in pediatric solid-organ transplant recipients during EBV+ Post-transplant Lymphoproliferative Disorder.docx by Ayantika Sen (13921581)

    Published 2022
    “…The objective of this study was to determine if changes in miR expression are associated with EBV+ PTLD. In this study, we have shown that miR-194 is significantly decreased in EBV+PTLD tumors and that additional miRs, including miRs-17, 19 and 106a are also reduced in EBV+PTLD as compared to EBV-PTLD. …”
  13. 2153

    Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

    Published 2022
    “…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC<sub>50</sub> at 2.1 μM. …”
  14. 2154

    Discovery of Betulinic Acid Derivatives as Potent Intestinal Farnesoid X Receptor Antagonists to Ameliorate Nonalcoholic Steatohepatitis by Chenlu Zhang (508309)

    Published 2022
    “…Evidence showed that intestinal FXR antagonism exhibited remarkable metabolic improvements in mice. Herein, we developed a series of betulinic acid derivatives as potent intestinal FXR antagonists, and <b>F6</b> was identified as the most potent one with an IC<sub>50</sub> at 2.1 μM. …”
  15. 2155

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  16. 2156

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  17. 2157

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  18. 2158

    Combination of DNA Damage, Autophagy, and ERK Inhibition: Novel Evodiamine-Inspired Multi-Action Pt(IV) Prodrugs with High-Efficiency and Low-Toxicity Antitumor Activity by Xiao-Meng Liu (778197)

    Published 2023
    “…Among them, compound <b>10</b> exhibited a 118-fold enhancement in the IC<sub>50</sub> value compared to cisplatin and low toxicity to normal cells. …”
  19. 2159
  20. 2160